zolbetuximab
astellas
[]
practice-changing research from #gi23: zolbetuximab + mfolfox6 meets primary endpoint in spotlight trial, improves pfs, os in pts w/ cldn18.2+, her2-negative, locally advanced unresectable or metastatic gastric or gej cancer: #ascodailynews #gicsm #esocsm
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.